Silver electroceutical technology to treat sarcopenia
While the world is rapidly transforming into a superaging society, pharmaceutical approaches to treat sarcopenia have hitherto not been successful due to their insufficient efficacy and failure to specifically target skeletal muscle cells (skMCs). Although electrical stimulation (ES) is emerging as an alternative intervention, its efficacy toward treating sarcopenia remains unexplored. In this study, we demonstrate a silver electroceutical technology with the potential to treat sarcopenia. First, we developed a high-throughput ES screening platform that can simultaneously stimulate 15 independent conditions, while utilizing only a small number of human-derived primary aged/young skMCs (hAskMC/hYskMC). The in vitro screening showed that specific ES conditions induced hypertrophy and rejuvenation in hAskMCs, and the optimal ES frequency in hAskMCs was different from that in hYskMCs. When applied to aged mice in vivo, specific ES conditions improved the prevalence and thickness of Type IIA fibers, along with biomechanical attributes, toward a younger skMC phenotype. This study is expected to pave the way toward an electroceutical treatment for sarcopenia with minimal side effects and help realize personalized bioelectronic medicine.
| Errataetall: |
ErratumIn: Proc Natl Acad Sci U S A. 2023 Oct 24;120(43):e2316531120. - PMID 37851679 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:120 |
|---|---|
| Enthalten in: |
Proceedings of the National Academy of Sciences of the United States of America - 120(2023), 33 vom: 15. Aug., Seite e2300036120 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kim, Min Young [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3M4G523W1G |
|---|
| Anmerkungen: |
Date Completed 09.08.2023 Date Revised 10.02.2024 published: Print-Electronic ErratumIn: Proc Natl Acad Sci U S A. 2023 Oct 24;120(43):e2316531120. - PMID 37851679 Citation Status MEDLINE |
|---|
| doi: |
10.1073/pnas.2300036120 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360489486 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360489486 | ||
| 003 | DE-627 | ||
| 005 | 20240210232609.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1073/pnas.2300036120 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1286.xml |
| 035 | |a (DE-627)NLM360489486 | ||
| 035 | |a (NLM)37549292 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kim, Min Young |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Silver electroceutical technology to treat sarcopenia |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.08.2023 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Proc Natl Acad Sci U S A. 2023 Oct 24;120(43):e2316531120. - PMID 37851679 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a While the world is rapidly transforming into a superaging society, pharmaceutical approaches to treat sarcopenia have hitherto not been successful due to their insufficient efficacy and failure to specifically target skeletal muscle cells (skMCs). Although electrical stimulation (ES) is emerging as an alternative intervention, its efficacy toward treating sarcopenia remains unexplored. In this study, we demonstrate a silver electroceutical technology with the potential to treat sarcopenia. First, we developed a high-throughput ES screening platform that can simultaneously stimulate 15 independent conditions, while utilizing only a small number of human-derived primary aged/young skMCs (hAskMC/hYskMC). The in vitro screening showed that specific ES conditions induced hypertrophy and rejuvenation in hAskMCs, and the optimal ES frequency in hAskMCs was different from that in hYskMCs. When applied to aged mice in vivo, specific ES conditions improved the prevalence and thickness of Type IIA fibers, along with biomechanical attributes, toward a younger skMC phenotype. This study is expected to pave the way toward an electroceutical treatment for sarcopenia with minimal side effects and help realize personalized bioelectronic medicine | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a electroceutical | |
| 650 | 4 | |a integrated electrical stimulation biochip | |
| 650 | 4 | |a multiplex screening technology | |
| 650 | 4 | |a personalized electric medicine | |
| 650 | 4 | |a sarcopenia | |
| 650 | 7 | |a Silver |2 NLM | |
| 650 | 7 | |a 3M4G523W1G |2 NLM | |
| 700 | 1 | |a Shin, Hyun Young |e verfasserin |4 aut | |
| 700 | 1 | |a Cho, Sung Chun |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Sohae |e verfasserin |4 aut | |
| 700 | 1 | |a Intisar, Aseer |e verfasserin |4 aut | |
| 700 | 1 | |a Woo, Hyeong Jung |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Youn-Suk |e verfasserin |4 aut | |
| 700 | 1 | |a You, Chang-Lim |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Jong-Sun |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Yun-Il |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Sang Chul |e verfasserin |4 aut | |
| 700 | 1 | |a Yea, Kyungmoo |e verfasserin |4 aut | |
| 700 | 1 | |a Oh, Tae Gyu |e verfasserin |4 aut | |
| 700 | 1 | |a Downes, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Evans, Ronald M |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Minseok S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Proceedings of the National Academy of Sciences of the United States of America |d 1915 |g 120(2023), 33 vom: 15. Aug., Seite e2300036120 |w (DE-627)NLM000008982 |x 1091-6490 |7 nnns |
| 773 | 1 | 8 | |g volume:120 |g year:2023 |g number:33 |g day:15 |g month:08 |g pages:e2300036120 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1073/pnas.2300036120 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 120 |j 2023 |e 33 |b 15 |c 08 |h e2300036120 | ||